Pacira BioSciences, Inc. (PCRX): Shareholders' Equity
$693.11M
As of 2025-12-31
$671.98M
As of 2026-06-30
-3.7%
3-year compound annual growth
+2.3%
5-year compound annual growth
+12.2%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $693.11M | -11.0% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $778.35M | -10.5% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $870.13M | +12.3% | 2026-02-26, Balance as of period end |
| 2022-12-31 | $775.01M | +6.1% | 2025-02-27, Balance as of period end |
| 2021-12-31 | $730.41M | +17.9% | 2024-02-29, Balance as of period end |
| 2020-12-31 | $619.69M | +74.6% | 2023-02-28, Balance as of period end |
| 2019-12-31 | $354.94M | +10.5% | 2022-02-28, Balance as of period end |
| 2018-12-31 | $321.23M | +14.9% | 2021-03-01, Balance as of period end |
| 2017-12-31 | $279.48M | +27.6% | 2020-02-21, Balance as of period end |
| 2016-12-31 | $218.98M | +0.3% | 2019-02-28, Balance as of period end |
| 2015-12-31 | $218.39M | +27.6% | 2018-02-28, Balance as of period end |
| 2014-12-31 | $171.15M | +314.9% | 2017-03-01, Balance as of period end |
| 2013-12-31 | $41.25M | -37.4% | 2016-02-25, Balance as of period end |
| 2012-12-31 | $65.86M | +36.4% | 2015-02-24, Balance as of period end |
| 2011-12-31 | $48.27M | n/m | 2014-02-25, Balance as of period end |
| 2010-12-31 | -$48.38M | n/m | 2013-03-07, Balance as of period end |
| 2009-12-31 | -$22.95M | n/a | 2012-03-27, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $693.11M | -11.0% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $788.80M | +7.7% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $1.06B | +2.5% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $522.60M | +8.2% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $647.80M | -4.7% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $567.61M | +29.5% |
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $301.68M | +31.8% |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | -$80.00M | n/m |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | $88.30M | +54.9% |
Compare PCRX, AMPH, SUPN, EBS side by side · Screen every company in Pharmaceutical Preparations ↗